Fluvoxamine for the treatment of COVID-19

Lancet Glob Health. 2022 Mar;10(3):e332. doi: 10.1016/S2214-109X(22)00006-7.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • COVID-19* / drug therapy
  • Fluvoxamine* / therapeutic use
  • Humans
  • SARS-CoV-2

Substances

  • Fluvoxamine

Supplementary concepts

  • COVID-19 drug treatment

Associated data

  • ClinicalTrials.gov/NCT04510194
  • ClinicalTrials.gov/NCT04885530